Pharma Chem Ltd.

ISO-9001 - 2015 - ISO-14001 - 2015

Date: 05.08.2026

To,
Department of Corporate Services,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Scrip Code: 524748

Dear Sir/Madam,

Sub: Outcome of Board Meeting held on 05th August, 2026.

Ref: Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015

Pursuant to Regulations 30 and 33 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of the Company, at its Meeting held today, i.e. 5th August, 2026, inter alia, considered and approved followings:

1. Unaudited Financial Results along with Limited Review Report for the quarter ended on 30th June, 2026.

The disclosures as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular No. SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated July 13, 2023 with regard to change in Directors and Key Managerial Personnel are enclosed herewith Annexure.

The meeting of the Board of Directors commenced at 12:15 p.m. and concluded at 02:00 p.m.

Kindly take the same on your record.

Thanking you,

Yours truly,
For Link Pharma Chem Limited

Komal Bhojwani

Digitally signed by Komal Bhojwani
DN: c=IN, o=Personal, postalCode=390024, l=Vadodara, st=Gujarat, street=B 188 natasha park 2 opp military boys hostel, Vadodara, Gujarat India- 390024-, title=5141, 2.5.4.20=47e18425f8bb2e0ce6421f3a9cf4f67df8f8a14e0149f36ebb15d73f0e679c35, serialNumber=95163e2947b283cd82b9d64169e906359933470915d884a5cf1b5655572cd56b, email=komalgolani13@gmail.com, cn=Komal Bhojwani
Date: 2026.08.05 14:13:06 +05'30'

Komal Bhojwani
Company Secretary & Compliance officer
Membership No.: A65594

Independent Auditor's Review Report on Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Link Pharma Chem Limited

1. We have reviewed the accompanying Statement of Unaudited Financial results of **Link Pharma Chem Limited** ("the Company") for the quarter ended 30th June, 2026 attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited financial results prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which, it is to be disclosed, or that it contains any material misstatement.

For **CNK & Associates LLP**
Chartered Accountants
Firm Registration No. 101961W/W-100036

Pareen Shah
Partner
Membership No. 125011
Place: Vadodara
Date: 05th August, 2026
UDIN: 26125011EHQDBW8510

CNK & ASSOCIATES LLP
VADODARA
CHARTERED ACCOUNTANTS

Link Pharma Chem Ltd.

ISO-9001-2015 - ISO-14001-2015 - ISO-45001-2018

LINK PHARMA CHEM LIMITED
CIN : L24230GJ1984PLC007540

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2026

Sr. No.	Particulars	Quarter ended			Year ended
		30th June 2026	31st March 2026	30th June 2025	31st March 2026
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Revenue from operations	876.84	658.88	781.48	2,743.15
	Other income	34.89	14.74	20.92	20.34
	Total Income (A)	**911.73**	**673.62**	**802.40**	**2,763.49**
2	**Expenses:**				
	Cost of materials consumed	378.00	210.77	269.69	1,061.76
	Changes in inventories of finished goods and work-in-progress	56.84	79.95	61.48	13.68
	Employee benefits expense	159.26	145.07	153.02	608.75
	Finance costs	14.22	15.29	10.40	52.98
	Depreciation and amortization expense	27.42	24.51	23.91	97.99
	Power and Fuel	79.11	66.83	86.36	323.31
	Other Expenses	158.01	180.20	146.56	591.52
	Total expenses (B)	**872.86**	**722.62**	**751.43**	**2,749.98**
3	**(Loss)/Profit before tax (C) = (A-B)**	**38.87**	**(49.00)**	**50.97**	**13.51**
4	**Tax expense:**				
	(1) Current tax	-	-	-	-
	(2) Deferred tax	7.04	(8.14)	10.78	5.82
	Total tax expense (D)	**7.04**	**(8.14)**	**10.78**	**5.82**
5	**(Loss)/Profit for the year/period (E) = (C-D)**	**31.83**	**(40.86)**	**40.19**	**7.69**
6	**Other Comprehensive Income**				
	Items that will not be reclassified to profit or loss				
	Net fair value gain on equity instruments through Other Comprehensive Income	(0.39)	(0.29)	0.32	0.06
	Remeasurement (loss) / gain of the defined benefit plan	1.66	8.61	(0.65)	6.66
	Income tax effect on above	(0.39)	(2.18)	0.18	(1.68)
	Total other comprehensive income for the year/period, net of tax (F)	0.88	6.13	(0.15)	5.04
7	**Total comprehensive income for the year/period (Net of Tax) (E+F)**	**32.71**	**(34.73)**	**40.03**	**12.73**
8	Paid up Equity share capital of Rs 10 each	444.06	444.06	444.06	444.06
9	Other Equity				834.86
10	Earnings per equity share (FV of Rs. 10) (Rs.)(Not annualised)				
	Basic and Diluted	0.72	(0.92)	0.91	0.17

CNK & ASSOCIATES LLP * VADODARA * CHARTERED ACCOUNTANTS

LINK PHARMA CHEM LIMITED *

Notes:

1 The above financial results for the Quarter ended on June 30, 2026 have been reviewed by Statutory auditors, recommended by the Audit Committee and have been approved and were taken on record by the Board of Directors at its meeting held on August 05, 2026.

2 The Company's operations fall under single segment namely "Manufacture and Sale of Chemicals".

3 As per the Ind AS 109 - 'Financial Instruments', the investment of the Company are valued at market prices and the difference between the cost and market value of the investments are accounted as part of Other Income. The break up of the reported figures are arrived as per working given hereunder.

Particulars		Quarter ended		Year ended
	30th June 2026	31st March 2026	30th June 2025	31st March 2026
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
Other income (A)	34.89	14.74	20.92	20.33
Fair value Net Gain/(loss) arising on financial asset designated as at FVTPL (B)	18.47	(2.86)	18.96	-
Adjusted Other Income (A-B)	**16.42**	**17.59**	**1.96**	**20.33**

5 The statement of financial results includes the result for the year ended March 31, 2026, being the balancing figures between the audited figures in respect of full financial year ended March 31,2026 and published unaudited year to date figures up to the 3rd quarter of the current financial year, which were subjected to a limited review, as required under the listings regulations.

CNK & ASSOCIATES LLP * VADODARA * CHARTERED ACCOUNTANTS

Date :05.08.2026
Place : Vadodara

For and on behalf of the Board of Directors of
Link Pharma Chem Limited

Satish Thakur
Chairman
(DIN:00292129)

LINK PHARMA CHEM LIMITED *